Ankylosing spondylitis and systemic sclerosis: a rare combination

Dieu-Donné Ouédraogo; Elisabeth Palazzo; Mireille Nlomé-Nzé; Nathalie Somogyi-Demerjian; Olivier Meyer

doi:10.1016/j.jbspin.2006.07.008

Ankylosing spondylitis and systemic sclerosis: a rare combination

Joint Bone Spine. 2009 May;76(3):290-2. doi: 10.1016/j.jbspin.2006.07.008. Epub 2009 Apr 15.

Authors

Dieu-Donné Ouédraogo¹, Elisabeth Palazzo, Mireille Nlomé-Nzé, Nathalie Somogyi-Demerjian, Olivier Meyer

Affiliation

¹ Service de Rhumatologie, CHU Bichat-Claude Bernard, 46 rue Henri Huchard, 75877 Paris Cedex 18, France.

PMID: 19372061
DOI: 10.1016/j.jbspin.2006.07.008

Abstract

We report a case of diffuse systemic sclerosis (skin, joints, esophagus, and Raynaud's phenomenon) in a 41-year-old Caucasian male with a 15-year history of ankylosing spondylitis and an episode of severe myocarditis of unknown origin. His HLA type included both the B27 allele conferring susceptibility to ankylosing spondylitis and the B35, DRB1 11, and DQB1 03 described as associated with systemic sclerosis. This case-report confirms that two inflammatory joint diseases may co-exist, particularly in patients carrying one or two susceptibility alleles to both diseases.

Publication types

Case Reports

MeSH terms

Adult
Anti-Inflammatory Agents / therapeutic use
Antirheumatic Agents / therapeutic use
Drug Therapy, Combination
HLA-B Antigens / genetics
Histocompatibility Testing
Humans
Male
Penicillamine / therapeutic use
Prednisone / therapeutic use
Scleroderma, Systemic / complications*
Scleroderma, Systemic / drug therapy
Scleroderma, Systemic / pathology
Spondylitis, Ankylosing / complications*
Spondylitis, Ankylosing / drug therapy
Spondylitis, Ankylosing / genetics
Spondylitis, Ankylosing / pathology
Treatment Outcome

Substances

Anti-Inflammatory Agents
Antirheumatic Agents
HLA-B Antigens
Penicillamine
Prednisone